JLE

L'Information Psychiatrique

MENU

Activité anxiolytique de la cyamémazine : rôle des récepteurs sérotoninergiques Volume 83, issue 7, Septembre 2007

Authors
Equipe d’Accueil EA2381 Université Paris VII, Hall de Biotechnologies, Tour 54, 2, place Jussieu, 75251 Paris Cedex 05, Service de psychiatrie adulte, CHU Saint-Antoine, 75015 Paris, Université Paris V, Inserm EMI-E0117, Paris, Sanofi-Aventis, Paris, Forenap, Rouffach, Hôpital Sainte-Marguerite, Marseille, Centre médico-pychologique, CHU Clermont-Ferrand

Anxiolytic properties of cyamemazine: the role of serotonin receptorsCyamemazine (Tercian ®), the most commonly prescribed neuroleptic in France, is often prescribed in association with other antipsychotic drugs. Clinicians value it because of its remarkable anxiolytic potential and its limited extrapyramidal effect. Recent neuropharmacological studies have revealed its powerful antagonistic effect on serotonin receptors, an effect which could help to account for its therapeutic profile. Work carried out on human monoaminergic receptors expressed on the membranes of transfected cells, on isolated organs and on whole animals shows cyamemazine’s greater affinity for 5HT 2A serotonin receptors than for D 2 dopamine receptors. Measurements carried on humans by means of imagery confirm this characteristic. The moderate fixation on D 2 receptors would thus seem to account for the low incidence of extrapyramidal effects during treatment with cyamemazin. Its high level of fixation on the 5HT 2 receptors could moreover contribute to the anxiolytic effect observed in human clinical study.